Study #2020-0564
A Phase II Basket Study of the ORAL TRK inhibitor Larotrectinib in Subjects with NTRK amplification positive and Pan TRK positive tumor
MD Anderson Study Status
Enrolling
Treatment Agent
Larotrectinib Sulfate
Description
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene amplification positive solid tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic). Larotrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Study phase:
Phase II
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.